Bob Edwards Vancouver – Education around cannabis and biggest cannabis companies today

Welcome back to Bob Edwards Vancouver Business blogs, today I will share with you the rest of the list of top 10 largest cannabis companies. 

2. Tilray > Market cap: $6.57 billion > Year-to-date price change: +215% (since Nasdaq listing in July 2018)

Tilray Inc. (NASDAQ: TLRY) is another Canada-based company that produces mainly medical marijuana. Following its Nasdaq listing in July, shares jumped nearly nine-fold before settling back down. The company did not even exist in 2017. Shares closed at $70.54 Monday, and the stock’s 52-week range is $20.10 to $300.00. The consensus price target on the stock is $140.00.

3. Aurora Cannabis > Market cap: $4.99 billion > Year-to-date stock price change: −91%

Aurora Cannabis Inc. (NASDAQ: ACB) is another Canadian company focused on growing and selling medical marijuana. In July, the company acquired grower CanniMed for $1.1 billion, and in May, Aurora paid $2.5 billion to acquire MedReLeaf, another Canadian marijuana grower (both were included in last year’s top 10). The company’s market cap has grown from $4.25 billion a year ago. Shares closed at $4.96 on Monday, and the stock’s 52-week range is $4.05 to $12.53. The consensus price target is $9.34.

4. Scotts Miracle-Gro > Market cap: $3.40 billion > Year-to-date stock price change: −43%

Most of this company’s activity in the marijuana market has been to acquire hydroponic growers and carve out space for itself as the leading supplier for indoor growers. The Scotts Miracle-Gro Co. (NYSE: SMG) saw its market cap fall by about 45% in 2018. Shares closed at $61.46 on Monday, and the stock’s 52-week range is $57.96 to $110.12. The consensus price target is $87.00.

5. GW Pharmaceuticals > Market cap: $3.15 billion > Year-to-date stock price change: −27%

GW Pharmaceuticals PLC (NASDAQ: GWPH) is a biopharmaceutical company that develops and commercializes therapeutics using a proprietary cannabinoid product platform. The firm’s CBD treatment for rare forms of epilepsy — Epidiolex — received U.S. Food and Drug Administration approval for sale in 2018, the first CBD product ever to do so. The company’s market cap dipped by about 6.9% in 2018. Shares closed at $97.39 on Monday, and the stock’s 52-week range is $95.75 to $179.65. The consensus price target is $173.17.

6. Cronos Group > Market cap: $1.87 billion > Year-to-date stock price change: +36% (since Nasdaq listing in February 2018)

Cronos Group Inc. (NASDAQ: CRON) is a Canada-based investment firm specializing in the marijuana market. The $1.8 billion Altria investment for a 45% stake in Cronos represents a fraction of the $12.8 billion Altria paid for a 35% stake in e-cigarette maker Juul. Cronos closed at $10.39 a share on Monday, and the 52-week trading range is $5.12 to $15.30. The consensus price target is $10.69.

7. Aphria > Market cap: $1.43 billion > Year-to-date stock price change: −53.5% (since NYSE listing in November)

Aphria Inc. (NYSE: APHA) is another Canada-based grower and seller of medical marijuana through retail stores and wholesale distribution. The company’s market cap dropped by 49% in 2018, and shares are down about 50% for the full year on the Toronto exchange. New York-traded shares closed at $5.69 on Monday, and the stock’s post-IPO range is $5.60 to $6.10. The consensus price target on the stock is $9.88.

8. Hexo > Market cap: C$933.4 million > Year-to-date price change: +11.1%

This Canada-based grower came public in early January of 2018. Hexo Corp. (TSX: HEXO) has a deal to supply up to 200,000 kg of cannabis over five years to the Quebec Crown corporation responsible for the cannabis trade in the province. The company is also seeking a U.S. listing on the NYSE American exchange. Shares closed at C$4.71 on Monday, and the stock’s 52-week range is C$3.70 to C$9.29. The consensus price target is C$8.89.

9. CannTrust > Market cap: C$692.34 million > Year-to-date share price change: −33.6%

CannTrust Holdings Inc. (TSX: TRST) produces and distributes medical and recreational cannabis products in Canada. The company expects to increase its annual growing capacity by 50,000 kg next year and by another 100,000 kg by the beginning of 2020. Shares closed at C$6.57 on Monday, and the stock’s 52-week range is C$5.86 to C$15.50. The consensus price target is C$14.51.

10. Green Organic Dutchman > Market cap: C$661.6 million > Year-to-date stock price change: +40.1% (since TSX listing in May 2018)

This cannabinoid product development firm is based in Ontario and is developing and marketing organic cannabis products. Aurora Cannabis has invested C$78 million in Green Organic Dutchman Holdings Ltd. (TSX: TGOD) and holds a purchase option on 20% of its organic products. Shares closed at C$2.46 on Monday, and the 52-week range is C$1.22 to C$10.24. The consensus price target is C$7.00.

Share prices fell across the board on the larger firms, even though their market caps increased as a result of investments from consumer products giants.


0 Comments

Leave a Reply

Your email address will not be published. Required fields are marked *